Incretin agents in type 2 diabetes
SA Ross, JM Ekoé - Canadian family physician, 2010 - cfp.ca
OBJECTIVE To evaluate the emerging classes of antihyperglycemic agents that target the
incretin pathway, including their therapeutic efficacy and side effect profiles, in order to help …
incretin pathway, including their therapeutic efficacy and side effect profiles, in order to help …
Incretin-based therapy in type 2 diabetes: an evidence based systematic review and meta-analysis
Incretin based therapies such as dipeptidyl peptidase-4 inhibitors (DPP-4i) and glucagon-
like peptide-1 receptor agonists (GLP-1Ra) are increasingly used for the treatment of Type 2 …
like peptide-1 receptor agonists (GLP-1Ra) are increasingly used for the treatment of Type 2 …
Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis
ContextPharmacotherapies that augment the incretin pathway have recently become
available, but their role in the management of type 2 diabetes is not well defined …
available, but their role in the management of type 2 diabetes is not well defined …
[HTML][HTML] Comparison of efficacy between incretin-based therapies for type 2 diabetes mellitus
Type 2 diabetes mellitus is widely prevalent and is often coexistent with obesity. Many of the
available treatment options have side effects such as weight gain which often affect patient's …
available treatment options have side effects such as weight gain which often affect patient's …
[HTML][HTML] Incretin therapy–present and future
AJ Garber - The review of diabetic studies: RDS, 2011 - ncbi.nlm.nih.gov
Although newer treatments for type 2 diabetes (T2D) patients have produced continual
improvements in outcome, a large and growing population with prediabetes remains under …
improvements in outcome, a large and growing population with prediabetes remains under …
Differentiating among incretin therapies: a multiple‐target approach to type 2 diabetes
S Cornell - Journal of Clinical Pharmacy and Therapeutics, 2012 - Wiley Online Library
What is known and Objective: Incretin‐based glucagon‐like peptide‐1 receptor agonists
(GLP‐1 RAs) and dipeptidyl peptidase‐4 (DPP‐4) inhibitor therapies provide glycaemic …
(GLP‐1 RAs) and dipeptidyl peptidase‐4 (DPP‐4) inhibitor therapies provide glycaemic …
Incretin‐based medications for type 2 diabetes: an overview of reviews
JM Gamble, A Clarke, KJ Myers… - Diabetes, Obesity …, 2015 - Wiley Online Library
Aims To summarize evidence from and assess the quality of published systematic reviews
evaluating the safety, efficacy and effectiveness of incretin‐based medications used in the …
evaluating the safety, efficacy and effectiveness of incretin‐based medications used in the …
Incretin-based therapies: review of current clinical trial data
A Peters - The American journal of medicine, 2010 - Elsevier
Incretin hormones are secreted in response to food ingestion and help manage glycemic
control by regulating insulin and glucagon release, slowing gastric emptying, and reducing …
control by regulating insulin and glucagon release, slowing gastric emptying, and reducing …
Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus
RK Campbell - Clinical therapeutics, 2011 - Elsevier
Background Glucose homeostasis is the result of a complex interaction of a spectrum of
hormones, including insulin, glucagon, amylin, and the incretins. Incretins are released by …
hormones, including insulin, glucagon, amylin, and the incretins. Incretins are released by …
Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction
S Russell - International Journal of Clinical Pharmacy, 2013 - Springer
Background Clinical trials comparing incretin-based therapies—glucagon-like peptide-1
receptor agonists (exenatide—twice daily and once weekly—and once-daily liraglutide) and …
receptor agonists (exenatide—twice daily and once weekly—and once-daily liraglutide) and …